在老年治疗中新兴的策略:从广谱老年溶解到精确重编程
Weidong Zhang1, Shijie Song1, Yue Zhang1
1Department of Burns and Cutaneous Surgery, Xijing Hospital, Xi'an, China.
npj aging
|March 11, 2026
概括
下一代老化药旨在选择性地消除衰老细胞,这些细胞驱动衰老和疾病. 三种新的策略,包括基于免疫的方法,PROTACs和微生物组调制,为与年龄相关的疾病提供精确疗法.
科学领域:
- 老年学和细胞生物学
- 免疫学和药理学
- 生物技术和治疗学
背景情况:
- 细胞衰老是衰老和与年龄相关的疾病的关键驱动因素,其特点是衰老细胞 (SnCs) 的积累.
- 通过与衰老相关的分泌表型 (SASP),SnCs促进炎症,并通过支持生存的途径逃避免疫清除.
- 第一代老化药物表现有前途,但有毒性和耐药性等局限性,需要先进的策略.
研究的目的:
- 审查和综合三个下一代老化策略,旨在克服早期药物的局限性.
- 为了探索基于免疫的老化,组织精密蛋白质溶解向化马体 (PROTACs) 和微生物组-表观遗传相互作用的老化疗法.
- 突出转向精密老年疗法治疗与年龄有关的疾病的转变.
主要方法:
- 基于免疫的老化:利用免疫瘤学原理通过阻断免疫抑制带,CAR T细胞或利用代谢漏洞来向SnCs.
- 组织精确性 PROTACs:使用招募 E3 酶的药物选择性降解抗亡蛋白质,可能减少系统性毒性.
- 微生物组-表观遗传相互作用:通过短链脂肪酸 (SCFA) 和饮食干预来调节肠-肝轴,以增强老化疗效和抑制SASP.
主要成果:
- 下一代策略可能提供更有针对性和个性化的老化疗法.
- 基于免疫的方法旨在增强SnCs的免疫清除.
- PROTACs提供了局部降解的亲生存蛋白质,和微生物组调制可以提高治疗效率和减少炎症.
结论:
- 精确老年治疗的发展,包括基于免疫,PROTAC和微生物组调节的策略,比第一代老年治疗药物取得了重大进展.
- 这些新的方法旨在提高治疗疗效,减少治疗与年龄相关的病理方面的全身毒性.
- 尽管有希望,但免疫病理学,制造,非目标效应和长期安全性等挑战需要进一步调查才能成功临床转化.
相关概念视频
Somatic to iPS Cell Reprogramming
2.8K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.8K
Introduction to Nuclear Reprogramming
2.4K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.4K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Methods of Nuclear Reprogramming
2.2K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.2K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K


